Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Cenegermin Eye Drops for Persistent Corneal Epithelial Defect
jRCT2061250102Phase 3Recruiting
- Sponsor
- Dompé
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in corneal persistent epithelial defect (PED) comparing Cenegermin ophthalmic solution with Vehicle ophthalmic solution (2 arms). Primary endpoint: Complete epithelial healing at week 4 maintained at week 8. Started Jun 2026; status: recruiting.
02
Drugs
cenegermin
03
Conditions
corneal persistent epithelial defect (PED)
Beyond the preview
Go deeper on jRCT2061250102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250102.